Navigating 1L Treatment Selection with BTKis in CLL

Across all dose levels of axatilimab, the 46-month OS rate was the 74.1% among patients with previously treated chronic graft-vs-host disease.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Zanubrutinib led to a 72% reduction in the risk of disease progression or death vs bendamustine/rituximab in this CLL/SLL population.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

The rate of 35% reduction in spleen volume or higher was higher pelabresib/ruxolitinib vs ruxolitinib alone in the MANIFEST-2 trial.

Data from the BRUIN-CLL-313 study may support pirtobrutinib as a new potential standard of care for those with untreated CLL or SLL.